APLS
STRONGApellis Pharmaceuticals, Inc.
CIK: 0001492422
Last activity: 4 days ago
Financial Metrics
As of Dec 31, 2024 (10-K)
Insider Roster (8 total, 8 active)
| Insider | Buys | Sells | Net Value | Holdings |
|---|---|---|---|---|
| Francois Cedric Chief Executive Officer | 0 | 3 | -$980K | 286,045 shares $6.23M |
| Watson David O. General Counsel | 0 | 4 | -$470K | 88,531 shares $1.93M |
| Sullivan Timothy Eugene Chief Financial Officer | 0 | 3 | -$367K | 93,901 shares $2.04M |
| Nicholson Nur Chief Technical Officer | 0 | 3 | -$270K | 71,118 shares $1.55M |
| Deschatelets Pascal Chief Scientific Officer | 0 | 3 | -$198K | 1,151,382 shares $25.06M |
| Baumal Caroline Chief Medical Officer | 0 | 3 | -$175K | 86,527 shares $1.88M |
| DeLong Mark Jeffrey Chief Business & Strat Officer | 0 | 4 | -$147K | 114,591 shares $2.54M |
| Chopas James George VP/Chief Accounting Officer | 0 | 3 | -$79K | 49,805 shares $1.08M |
Recent Transactions
368 shares @ $22.15
$8K
Feb 11, 2026
27,192 shares @ $21.77
$592K
Jan 22, 2026
10,287 shares @ $21.77
$224K
Jan 22, 2026
7,832 shares @ $21.77
$170K
Jan 22, 2026
7,725 shares @ $21.77
$168K
Jan 22, 2026
5,928 shares @ $21.77
$129K
Jan 22, 2026
3,371 shares @ $21.77
$73K
Jan 22, 2026
2,797 shares @ $21.77
$61K
Jan 22, 2026
2,064 shares @ $21.77
$45K
Jan 22, 2026
8,182 shares @ $19.79
$162K
Jan 20, 2026
2,892 shares @ $19.79
$57K
Jan 20, 2026
2,475 shares @ $19.79
$49K
Jan 20, 2026
2,203 shares @ $19.79
$44K
Jan 20, 2026
1,882 shares @ $19.79
$37K
Jan 20, 2026
1,334 shares @ $19.79
$26K
Jan 20, 2026
909 shares @ $19.79
$18K
Jan 20, 2026
726 shares @ $19.79
$14K
Jan 20, 2026
10,186 shares @ $22.19
$226K
Jan 13, 2026
5,780 shares @ $22.19
$128K
Jan 13, 2026
3,856 shares @ $22.19
$86K
Jan 13, 2026
2,618 shares @ $22.19
$58K
Jan 13, 2026
2,277 shares @ $22.19
$51K
Jan 13, 2026
1,780 shares @ $22.19
$39K
Jan 13, 2026
873 shares @ $22.19
$19K
Jan 13, 2026
3,020 shares @ $25.53
$77K
Jan 5, 2026
5,000 shares @ $24.49
$122K
Dec 16, 2025
⚠️ Important Disclaimer
• This is AI-generated analysis for educational purposes only, not financial advice.
• Insider trading data is derived from SEC Form 4 filings and may contain errors.
• Always conduct your own research and consult qualified financial advisors before making investment decisions.